Randomized controlled trialHumanClinical Trial, Phase II

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

The New England journal of medicine, 2023 Aug 10. Jastreboff AM, Kaplan LM, Frías JP and 8 others.

Study type

Randomized controlled trial · Clinical Trial, Phase II

Subjects

Human participants (PubMed MeSH: Humans)

Journal

The New England journal of medicine

Published

2023 Aug 10

PubMed

PMID 37366315 ↗

DOI

10.1056/NEJMoa2301972 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Retatrutide →peptide tier list 2026 →retatrutide what we know →semaglutide vs tirzepatide vs retatrutide →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AdultFemaleHumansMaleBody Mass IndexDouble-Blind MethodGlucagon-Like Peptide 1ObesityTreatment OutcomeWeight LossGastric Inhibitory PolypeptideReceptors, Glucagon

Other papers on Retatrutide

Randomized controlled trial · 2023

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page